Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Receivables: 2009-2024

Historic Change in Receivables for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to -$47.2 million.

  • Ironwood Pharmaceuticals' Change in Receivables rose 88.96% to $34.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.2 million, marking a year-over-year increase of 191.35%. This contributed to the annual value of -$47.2 million for FY2024, which is 5012.12% down from last year.
  • As of FY2024, Ironwood Pharmaceuticals' Change in Receivables stood at -$47.2 million, which was down 5,012.12% from -$924,000 recorded in FY2023.
  • Ironwood Pharmaceuticals' Change in Receivables' 5-year high stood at -$924,000 during FY2023, with a 5-year trough of -$47.2 million in FY2024.
  • Moreover, its 3-year median value for Change in Receivables was -$8.0 million (2022), whereas its average is -$18.7 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Change in Receivables skyrocketed by 88.44% in 2023, and later tumbled by 5,012.12% in 2024.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Change in Receivables stood at -$4.1 million in 2020, then plummeted by 88.51% to -$7.7 million in 2021, then declined by 3.64% to -$8.0 million in 2022, then skyrocketed by 88.44% to -$924,000 in 2023, then tumbled by 5,012.12% to -$47.2 million in 2024.